CSL Overview

  • Founded
  • 1916

Founded
  • Status
  • Public

  • Employees
  • 30,000

Employees
  • Stock Symbol
  • CSL

Stock Symbol
  • Investments
  • 9

  • Share Price
  • $181.66

  • (As of Wednesday Closing)

CSL General Information

Description

CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include non-plasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.

Contact Information

Website
www.csl.com
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
ASX
Primary Office
  • 45 Poplar Road
  • Parkville, Victoria 3052
  • Australia
+61 (03) 0000 0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CSL Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$181.66 $184.22 $171.24 - $235.24 $87.6B 482M 770K $4.81

CSL Financials Summary

In Thousands,
USD
TTM 30-Jun-2022 FY 2022 30-Jun-2022 FY 2021 30-Jun-2021 FY 2020 30-Jun-2020
EV 88,379,872 88,379,872 101,519,725 94,338,359
Revenue 10,493,100 10,493,100 10,265,300 9,100,500
EBITDA 3,482,700 3,482,700 3,625,300 3,136,300
Net Income 2,254,700 2,254,700 2,375,000 2,102,500
Total Assets 28,346,000 28,346,000 18,156,900 15,464,600
Total Debt 9,657,800 9,657,800 5,806,900 5,992,800
Public Fundamental Data provided by Morningstar, Inc. disclaimer

CSL Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore CSL‘s full profile, request access.

Request a free trial

CSL Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived pro
Biotechnology
Parkville, Australia
30,000 As of 2022
00.000
000000000 00.000

0000 0

re dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur
000000000000000
Petah Tikva, Israel
00000 As of 0000
00000
00000000000 00000

000000

mmodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fug
0000000000000
Beijing, China
0000 As of 0000
00000
0000000 0000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CSL Competitors (16)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Teva Pharmaceutical Industries Corporate Backed or Acquired Petah Tikva, Israel 00000 00000 00000000000 00000
0000000 0000000000 Private Equity-Backed Beijing, China 0000 00000 0000000 0000 00000
00000 Corporation Basel, Switzerland 000000 00.000 00000000000 00.000
0000 0000000 Corporation Bagsvaerd, Denmark 00000 000000000
00000000000 Formerly PE-Backed Cambridge, United Kingdom 00000 00.000 00000000 00.000
You’re viewing 5 of 16 competitors. Get the full list »

CSL Patents

CSL Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022902289-A0 Methods of treating metabolic disorders Pending 12-Aug-2022
AU-2022900636-A0 Method of treating an eosinophil-associated disease Pending 16-Mar-2022
AU-2022900484-A0 Methods of bone marrow conditioning Pending 01-Mar-2022
AU-2021904136-A0 Protein formulations and uses thereof Pending 20-Dec-2021
AU-2021903946-A0 Method of treating an eosinophil-associated disease Pending 07-Dec-2021
To view CSL’s complete patent history, request access »

CSL Executive Team (4)

Name Title Board Seat Contact Info
Joy Linton Chief Financial Officer
Bill Campbell Executive Vice President & Chief Commercial Officer
Mark Hill Chief Digital Information Officer
Paul Perreault Chief Executive Officer & Board Member
To view CSL’s complete executive team members history, request access »

CSL Board Members (11)

Name Representing Role Since
00000 0000000 CSL Chairman & Board Member 000 0000
00000 00000 CSL Board Member 000 0000
0000000 000000 CSL Board Member 000 0000
000000000 0'000000 Self Board Member 000 0000
00000 0000000 Self Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

CSL Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CSL Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore CSL‘s full profile, request access.

Request a free trial

CSL Investments & Acquisitions (9)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000 00000 09-Aug-2022 0000000000 000.00 Pharmaceuticals 0000 0000
000 000000000 15-Jun-2021 00000 0000 000.00 Drug Discovery
00000000 26-Sep-2019 00000 0000 000.00 Drug Discovery
000000000 11-Sep-2017 0000000000 00000 Biotechnology 0000 0000
Wuhan Zhong Yuan Rui De Biological Products 03-Aug-2017 Merger/Acquisition 00000 Drug Discovery 0000 0000
You’re viewing 5 of 9 investments and acquisitions. Get the full list »

CSL Subsidiaries (4)

Company Name Industry Location Founded
CSL Plasma Acquirer 2019
0000000 Other Pharmaceuticals and Biotechnology Holly Springs, NC 0000
000000000 Biotechnology Tucson, AZ 0000
000 00000 Pharmaceuticals Glattbrugg, Switzerland 0000
To view CSL’s complete subsidiaries history, request access »

CSL Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
0000000000000 0000 09-Apr-2006 00000 00000 00 000 Completed
  • 3 buyers
To view CSL’s complete exits history, request access »